Summary & Overview
HCPCS Level II J1072: Testosterone Cypionate (azmiro) Injection, 1 mg
HCPCS Level II code J1072 designates the injectable drug testosterone cypionate (azmiro), 1 mg and is used to bill for the medication supplied for parenteral administration. This code matters nationally because testosterone replacement therapies are commonly administered in outpatient and office-based settings for a range of FDA-approved indications and monitored treatment plans. Precise drug-level coding affects pharmacy reimbursement, medical benefit charge capture, and utilization reporting across commercial and public payers.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing context for J1072, including typical sites of service and service type, payer coverage considerations, and where to look for policy and reimbursement guidance. The publication also summarizes common modifier usage and coding relationships where available and identifies gaps where input data was not provided.
This national-focused summary is intended to orient billing managers, clinicians, and revenue cycle staff to the clinical and administrative role of HCPCS Level II code J1072 and to indicate the topics covered in the full publication: benchmarks, policy references, clinical context, and coding considerations.
Billing Code Overview
HCPCS Level II code J1072 represents an injectable formulation of testosterone cypionate (azmiro), 1 mg. This code is used to bill for the drug product supplied for administration as an intramuscular injection.
-
Service type: Drug administration (injectable medication)
-
Typical site of service: Physician office, outpatient clinic, or other facility where parenteral medications are administered
Clinical & Coding Specifications
Clinical Context
A 34-year-old male with primary hypogonadism presents to an outpatient endocrinology clinic for initiation of intramuscular testosterone therapy. After evaluation including serum total testosterone, LH/FSH, and discussion of risks and benefits, the clinician prescribes testosterone cypionate (azmiro) administered intramuscularly. The patient returns to the clinic every 1–2 weeks for direct observed administration or receives instruction for home administration by a trained clinician or caregiver. Typical workflow: verify indication and informed consent; review allergies, medication reconciliation, and baseline labs; prepare dose (milligram strength derived from vial concentration); select injection site (preferably the gluteal or lateral thigh muscle); perform standard infection control and aseptic technique; administer J1072 for the drug product; monitor patient for immediate adverse reaction for 15–30 minutes; document lot number, expiration date, dose, site, route, and any adverse events; schedule follow-up labs and dose titration visits. Typical site of service is outpatient clinic, physician office, or ambulatory infusion/medication administration area. Emergency department or inpatient use may occur for acute management but is less common. Common payors for authorization and claims coordination include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier or not otherwise specified |